FDA Approves Veklury to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
This Approval Supports Veklury’s Strong Safety Profile and Makes Veklury the Only Approved COVID-19 Antiviral Treatment Across all…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Aug 23
This Approval Supports Veklury’s Strong Safety Profile and Makes Veklury the Only Approved COVID-19 Antiviral Treatment Across all…
25 Aug 23
Brand begins Its Next Era as new logo and packaging begins to roll into Marketplace
25 Aug 23
The special volunteer event was part of the company’s ongoing commitment to fighting hunger and included a $5,000…
25 Aug 23
Industry Icon Leaves Legacy of Advancing Diversity, Equity and Inclusion
25 Aug 23
Polpharma Biologics, an international biotech company dedicated to the development and manufacture of biosimilars, announced today that the…
24 Aug 23
FDA accepted Pfizer and Astellas’ supplemental New Drug Application (sNDA) for Xtandi, expanding its indication to include patients…
24 Aug 23
With ODD, NXC-201 is now eligible for seven years of US market exclusivity in the US upon regulatory…
24 Aug 23
The funding, which follows the firm’s launch with a $100m Series A financing in March this year, will…
24 Aug 23
Under the terms of the agreement, Aardvark Therapeutics will have the global development and commercialisation rights to ADAIR…
24 Aug 23
The expansion significantly boosts cell therapy capabilities and serves as a complementary addition to suspension and adhesion viral…